Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This overview highlights the Dermatologic Surgery journal's comprehensive coverage of dermatologic surgical procedures, but it reports no new research findings.

In this study, Juvéderm repeat treatments maintained wrinkle correction in nasolabial folds for up to 21 months and required significantly less filler than the initial treatment, indicating potential benefits for patients.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This article discusses barriers to obtaining JAK inhibitor therapy for patients with alopecia areata and highlights that racial inequities may worsen these difficulties; it calls for further advocacy to improve access.

This review discusses the potential biomedical applications of Janus membranes, especially in wound healing, and emphasizes the challenges and future prospects in their development, but reports no new experimental results.

This study found that JAK inhibitor treatment in patients with alopecia areata was associated with a lower incidence of major depressive disorder and decreased antidepressant usage.

This paper creatively examines whether the name "Janus" in Janus kinase inhibitors foreshadows their dual role in the treatment of dermatological conditions, drawing parallels to the Roman god Janus's dual nature and influence over beginnings and transitions.

This study demonstrated that transplanting in vitro differentiated Wharton's jelly mesenchymal stem cells on acellular dermal grafts led to complete skin regeneration with appendages in a mouse model of full-thickness wounds.

This abstract describes a waxing procedure that removes hair and dead skin cells, leaving the skin smooth, but it reports no new research findings.

This article describes Amy Senior's evolving views on the Joint Council for Cosmetic Practitioners and reports no new research findings.

This abstract describes the Dermatologic Surgery journal, which publishes peer-reviewed articles on cosmetic and reconstructive skin surgery, but reports no new clinical findings.

This study found that a novel cross-linked hyaluronic acid dermal filler is safe and effective for improving lip enhancement, cheekbone augmentation, and nasolabial folds across different skin types, with significant improvements in wrinkle severity and overall facial aesthetics observed.

This article discusses the JCCP's new Premises Standards for aesthetic practitioners, focusing on how these guidelines help ensure patient safety, and reports no new research findings.

This article is a letter to the editor discussing positive Jacquet's sign in traction alopecia and provides no new research results.

This document is a thesis or dissertation backed by the Université du Québec à Trois-Rivières, and it provides no new research findings.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

This editorial summarizes key dermatological insights and learnings from the 2022 Dermatology Nurses' Association Convention, covering conditions like lichen sclerosus and melanoma, and issues related to nail disorders and skin of color.

This letter to the editor presents a case of non-Herlitz junctional epidermolysis bullosa associated with a COL17A1 mutation and reports no new clinical findings.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

In this study, researchers developed a method using stencils to create controlled stiffness gradients in alginate hydrogels, revealing that stiffer regions within the gels promote deeper invasion by breast cancer cells, facilitating the study of mechanosensitive cellular behaviors.

The authors highlighted promising developments in JAK inhibitors as targeted treatments for skin diseases such as atopic dermatitis, psoriasis, and alopecia areata, noting their effectiveness and safety profiles. Recent advances also suggest potential for treating melanoma with these inhibitors.

In 2021, JAMA Dermatology published significant findings on skin conditions post-COVID vaccination, melanoma surveillance, atopic dermatitis treatments, and confirmed that sun protection does not harm bone health.

This study found that Juvéderm Ultra Plus was safe and effective for correcting severe nasolabial folds in a Chinese population, requiring less volume than Restylane while achieving similar responder rates, with fewer severe treatment site reactions.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

Deuruxolitinib is generally safe for treating alopecia areata.